drug delivery

Advantageous Systems LLC (ADS) is a global company integrating nanotechnology, material science, and biotechnology to produce smart materials with unique functional characteristics. Applications include medical devices, therapeutics, and clean technology products. ADS produces patented water remediation and desalination technology using supramolecular chemistry and nanotechnology, and is developing a minimally-invasive point-of-care diagnostic device and novel small molecule therapeutics.

desalinationnanotechnologypre-clinical researchsupramolecular chemistrywater treatment

Akagera Medicines is a private Delaware-registered company founded in 2018 in Kigali, Rwanda, that develops novel and patented liposomal formulations of antibacterial drugs to treat tuberculosis and other infectious diseases. It is majority-owned by the people of Rwanda and has laboratories in Boston and San Francisco, plus a 100%-owned subsidiary in Kigali registered in 2022 for future manufacturing and clinical trials.

clinical trialsin vitro testingliposomal formulationmanufacturing (planned)medicinal chemistrypre-clinical studiessmall-molecule drug engineering

AnelleO is harnessing advancements in 3D printing technology for novel solutions in women's health. Its first products are Intravaginal Rings (IVRs), a non-invasive, self-administered and retrievable platform for sustained delivery of therapeutics over days to months. AnelleO has designed and is manufacturing ANLO102, an intravaginal ring system that releases progesterone over approximately 28 days for progesterone supplementation in assisted reproductive technology (ART).

3D printingdevice engineering

Bexorg is a neuroscience company spun out of Yale University that built the first-ever whole-human brain perfusion model, the BrainEx platform. The platform restores molecular activity in donated whole-human brains, creating a translational model to generate clinically predictive data and accelerate CNS drug discovery, addressing root causes of CNS clinical trial failures before programs enter the clinic.

AI platformclinically relevant disease modelsgeneration of clinically predictive datawhole-brain perfusion

Aphios is a clinical-stage biotechnology company developing differentiated medicines through SuperFluids™ manufacturing and advanced drug delivery. Its lead program, Zindol®, is being prepared for Phase 3 development for chemotherapy-induced nausea and vomiting. The company holds 85+ issued patents and has received more than $20 million in NIH grant funding. Founder, President & CEO is Dr. Trevor P. Castor.

co-developmentdrug discoverydrug manufacturinglicensingnanotechnology drug formulation and deliverypathogen reductionpurificationsupercritical-fluid extraction and fractionationSuperFluids™ manufacturing

Dsquare is a fully integrated specialty healthcare products company based in Caguas, Puerto Rico, developing and manufacturing pharmaceuticals and food supplements from bench to market in the US, Canada and Europe. It develops proprietary and client products using advanced technologies, enabling domestic production and reshoring manufacturing of active ingredients and finished dosage forms to Puerto Rico. The team includes experts in clinical medicine, research, chemical engineering, chemistry and AI-driven automation.

clinical trial batch up-scalingdossier developmentformulation developmentmanufacturingregulatory filingstrategic advisory

of page Unlocking The True Potential Of The World's Therapeutics Learn more about our groundbreaking technology COLLABORATE WITH US What we do Our research ABOUT US LEARN MORE Our Technology PIPELINE ABOUT USHera Health Solutions is a biotechnology company specializing in the research, development, and commercialization of a proprietary nanotechnology-enabled platform for transforming existing therapeutics into more effective and long-acting therapies.LATEST NEWSHera Health Solutions Technology Featured on Entrepreneur Magazine READ ARTICLE READ ARTICLE Newest Contract Partnership in 2025 Highlighted in Business Journal READ ARTICLE Hera Health Solutions Global Pharmaceutical Contract Announcement PROPRIETARY NANOTECHNOLOGY ENABLES THE RAPID REFORMULATION OF EXISTING APIs Pioneering the Future of Drug Delivery Upgraded and Customizable Release Profiles FDA & GMP-Approved Manufacturing &.

commercializationdevelopmentFDA & GMP-approved manufacturingreformulation of APIsresearch